semaglutide patent expiration 2031 Off-patent in 2026: the next revolution in anti-obesity medications Looming GLP-1 drug patent expirations

The identification of the pleiotropic SNP PMSnpB394 , associated with 14 vigor and longevity-related traits, highlights genomic regions of major effect influencing seed performance and viability

These numbers exceeded the Phase 2 results, partly because the trial ran longer (68 weeks versus 48 weeks) and partly because the dose escalation schedule was refined

Key finding: Unprecedented mitochondria-to-nucleus communication pathway for metabolic adaptation

I am looking forward to when the Tirzepatide kicks in

The researchers reported that at the end of a 24-week treatment period, subjects who received semaglutide had significant improvements in knee joint function